Isosorbide Dinitrate

Isosorbide Dinitrate

SCHEMBL1553054

O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-].O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GUCY1A1GUCY1A2GUCY1B1GUCY1B2

The experimentally established mechanism targets of Isosorbide Dinitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 1.00
MAPT P10636 1/20 0.78
BCHE P06276 6/20 0.64
GSR P00390 8/20 0.46
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isosorbide Dinitrate SCHEMBL19528695 1.00 ALDH1A1 (1.00) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL9439417 1.00 ALDH1A1 (1.00) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL29532755 1.00 ALDH1A1 (1.00) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL8253 1.00 ALDH1A1 (1.00) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL309369 1.00 ALDH1A1 (1.00) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL3008938 0.98 ALDH1A1 (0.95) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL714959 0.98 ALDH1A1 (0.95) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL27976716 0.96 ALDH1A1 (0.91) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL28209664 0.96 ALDH1A1 (0.91) ALDH1A1MAPTBCHEGSRCA2
Isosorbide Dinitrate SCHEMBL3864281 0.94 ALDH1A1 (0.88) ALDH1A1MAPTBCHEGSRCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383634-A1 MEDICAL SYSTEM FOR SEAMLESS THERAPY ADJUSTMENT MEDTRONIC, INC. 2020-12-10 US disclosed
EP-1456670-B8 METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS CAMBRIDGE THERANOSTICS LTD (GB) 2011-04-27 EP disclosed
CN-101896161-A Solid formulations of crystalline compounds PURDUE RESEARCH FOUNDATION 2010-11-24 CN disclosed
US-20100222311-A1 SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS PURDUE RESEARCH FOUNDATION (US) 2010-09-02 US disclosed
EP-1456670-B1 METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS CAMBRIDGE THERANOSTICS LTD (GB) 2009-07-15 EP disclosed
EP-1454140-B1 DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS CAMBRIDGE THERANOSTICS LTD (GB) 2009-07-08 EP disclosed
US-7504226-B2 Methods relating to treatment of atherosclerosis CAMBRIDGE THERANOSTICS LTD. (GB) 2009-03-17 US disclosed
US-7419657-B2 Reducing antibody-mediated lipid peroxidation activity in vascular systems; idiotypic antibodies; chlamydia pneumoniae vaccines CAMBRIDGE THERANOSTICS LTD. (GB) 2008-09-02 US disclosed
US-7148028-B2 Methods and means relating to atherosclerosis CAMBRIDGE THERANOSTICS LTD. (GB) 2006-12-12 US disclosed
EP-1456670-A2 METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS Cambridge Theranostics Ltd. (GB) 2004-09-15 EP disclosed
EP-1454140-A2 DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS Cambridge Theranostics Ltd. (GB) 2004-09-08 EP disclosed
WO-2003019198-A2 METHODS RELATING TO TREATMENT OF ATHEROSCLEROSIS CAMBRIDGE THERANOSTICS LTD (GB) 2003-03-06 WO disclosed
WO-2003019196-A2 DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS CAMBRIDGE THERANOSTICS LTD (GB) 2003-03-06 WO disclosed
US-5700516-A WATERPROOFING PAPER S. C. JOHNSON COMMERICAL MARKETS, INC. (US) 1997-12-23 US disclosed